A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Exclusion Criteria

• •A. Prior Ocular Treatment Study Eye
• •History of vitrectomy surgery, submacular surgery, or other surgical intervention, all for AMD
• •Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy
• •Previous treatment with corticosteroid IVT injection
• •Previous intraocular device implantation (not including intraocular lens implants)
• •Previous laser (any type) used for age-related macular degeneration (AMD) treatment
• •Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit
• •Prior treatment with intravitreal treatments for geographic atrophy
• •Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PDS implant
• •Either Eye
• •Prior treatment with brolucizumab
• •Prior gene therapy for nAMD or other ocular diseases
• •Previous participation in any ocular disease studies of investigational drugs and/or devices, within 3 months or five elimination half-lives of the investigational therapy, whichever is longer, preceding the screening visit
• •B. Choroidal Neovascularization (CNV) Lesion Characteristics
• •Study Eye
• •Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5 disc area (1.27 millimeter square \[mm\^2\]) in size at screening
• •Subfoveal fibrosis or subfoveal atrophy
• •Either Eye • CNV due to other causes, such as ocular histoplasmosis, trauma, central serous chorio-retinopathy, or pathologic myopia
• •C. Concurrent Ocular Conditions Study Eye
• •Retinal pigment epithelial tear
• •Any concurrent intraocular condition
• •Active intraocular inflammation (grade trace or above)
• •History of vitreous hemorrhage
• •History of rhegmatogenous retinal detachment
• •History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the randomization visit
• •History of pars plana vitrectomy surgery
• •Aphakia or absence of the posterior capsule
• •Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia
• •Preoperative refractive error that exceeds 8 diopters of myopia, for participants who have undergone prior refractive or cataract surgery
• •Intraocular surgery (including cataract surgery) within 3 months preceding the randomization visit
• •Uncontrolled ocular hypertension or glaucoma
• •History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
• •History of corneal transplant
• •Fellow (Non-Study) Eye
• •Non-functioning fellow eye
• •Either Eye
• •Any history of uveitis
• •Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis